Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) have received an average recommendation of “Moderate Buy” from the fourteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $34.1667.

Several research analysts have recently commented on the company. Evercore set a $33.00 price objective on Dyne Therapeutics in a research note on Friday, May 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. TD Cowen assumed coverage on shares of Dyne Therapeutics in a report on Friday, June 26th. They set a “buy” rating on the stock. Wall Street Zen upgraded shares of Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday. Finally, Sanford C. Bernstein increased their price objective on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Jason P. Rhodes sold 309,268 shares of the stock in a transaction on Friday, June 26th. The stock was sold at an average price of $21.28, for a total value of $6,581,223.04. Following the completion of the sale, the director owned 1,016,633 shares in the company, valued at approximately $21,633,950.24. This represents a 23.33% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have acquired 9,000 shares of company stock valued at $156,800 and have sold 2,334,279 shares valued at $46,221,906. Corporate insiders own 9.46% of the company’s stock.

Institutional Investors Weigh In On Dyne Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DYN. Perceptive Advisors LLC increased its holdings in Dyne Therapeutics by 34.2% in the 1st quarter. Perceptive Advisors LLC now owns 4,668,839 shares of the company’s stock valued at $84,646,000 after acquiring an additional 1,189,895 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Dyne Therapeutics by 63.5% in the first quarter. Bank of America Corp DE now owns 1,443,313 shares of the company’s stock worth $26,167,000 after buying an additional 560,391 shares in the last quarter. California State Teachers Retirement System lifted its position in shares of Dyne Therapeutics by 15.6% in the first quarter. California State Teachers Retirement System now owns 139,663 shares of the company’s stock worth $2,532,000 after buying an additional 18,863 shares in the last quarter. Royal Bank of Canada boosted its stake in Dyne Therapeutics by 267.6% during the first quarter. Royal Bank of Canada now owns 68,188 shares of the company’s stock valued at $1,236,000 after buying an additional 49,641 shares during the last quarter. Finally, Rock Springs Capital Management LP boosted its stake in Dyne Therapeutics by 6.5% during the first quarter. Rock Springs Capital Management LP now owns 972,198 shares of the company’s stock valued at $17,626,000 after buying an additional 59,243 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Up 4.3%

DYN opened at $23.83 on Friday. The firm’s 50 day simple moving average is $18.89 and its two-hundred day simple moving average is $18.24. The company has a market capitalization of $3.94 billion, a PE ratio of -7.40 and a beta of 1.06. Dyne Therapeutics has a 1-year low of $8.24 and a 1-year high of $25.00. The company has a current ratio of 19.92, a quick ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same period in the prior year, the firm earned ($1.05) earnings per share. As a group, equities analysts forecast that Dyne Therapeutics will post -3.02 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.